Capital Fund Management S.A. purchased a new stake in Cantel Medical Corp. (NYSE:CMD) in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 4,800 shares of the company’s stock, valued at approximately $374,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Thompson Davis & CO. Inc. acquired a new position in Cantel Medical Corp. in the 2nd quarter valued at $238,000. Martingale Asset Management L P acquired a new position in Cantel Medical Corp. in the 2nd quarter valued at $3,265,000. Alliancebernstein L.P. acquired a new position in Cantel Medical Corp. in the 2nd quarter valued at $4,770,000. HPM Partners LLC acquired a new position in Cantel Medical Corp. in the 2nd quarter valued at $252,000. Finally, Wells Fargo & Company MN acquired a new position in Cantel Medical Corp. in the 2nd quarter valued at $75,715,000. Institutional investors own 83.79% of the company’s stock.

Several brokerages have weighed in on CMD. Needham & Company LLC reiterated a “hold” rating on shares of Cantel Medical Corp. in a report on Friday, September 1st. Zacks Investment Research raised shares of Cantel Medical Corp. from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Sidoti raised shares of Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price objective for the company in a research note on Wednesday, August 2nd. Finally, Benchmark Co. cut shares of Cantel Medical Corp. from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $91.67.

In other Cantel Medical Corp. news, Chairman Charles M. Diker sold 35,000 shares of the stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $75.52, for a total value of $2,643,200.00. Following the completion of the sale, the chairman now owns 3,114,520 shares in the company, valued at approximately $235,208,550.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 14.90% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/19/capital-fund-management-s-a-purchases-shares-of-4800-cantel-medical-corp-cmd.html.

Shares of Cantel Medical Corp. (NYSE:CMD) opened at 85.95 on Tuesday. Cantel Medical Corp. has a 52 week low of $68.19 and a 52 week high of $88.81. The stock has a market capitalization of $3.57 billion, a PE ratio of 50.86 and a beta of 1.23. The stock’s 50 day moving average is $78.25 and its 200 day moving average is $76.58.

About Cantel Medical Corp.

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Want to see what other hedge funds are holding CMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cantel Medical Corp. (NYSE:CMD).

Institutional Ownership by Quarter for Cantel Medical Corp. (NYSE:CMD)

Receive News & Stock Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related stocks with our FREE daily email newsletter.